# A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

> **NCT01241591** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1101 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CP 690,550 5 mg
- **DRUG:** CP 690,550 10 mg
- **BIOLOGICAL:** Etanercept 50 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01241591
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 1101 (ACTUAL)
- **Last updated:** 2018-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241591, "A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01241591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*